Literature DB >> 22112609

Patterns of recurrence in 1988 FIGO stage IC endometrioid endometrial cancer.

Kara C Long1, Qin Zhou, Martee L Hensley, Kaled M Alektiar, Jacob Gomez, Ginger J Gardner, Dennis S Chi, Richard R Barakat, Nadeem R Abu-Rustum.   

Abstract

OBJECTIVES: To evaluate patterns of recurrence in 1988 FIGO stage IC endometrioid endometrial adenocarcinoma.
METHODS: A prospectively maintained endometrial cancer database was utilized to identify all patients with stage IC endometrioid endometrial adenocarcinoma treated between 2/93 and 6/09. Patterns of recurrence and risk factors were analyzed.
RESULTS: One hundred thirty-four patients with stage IC endometrial cancer were identified. Median age was 66 years (range, 31-91 years). All patients were initially treated surgically, and 79% underwent comprehensive surgical staging with lymphadenectomy. Median number of lymph nodes removed was 18 (range, 1-45). Fifty-one patients (38%) had FIGO grade 1 tumors, 55 (41%) had grade 2 tumors, and 28 (21%) had grade 3 tumors. The majority of patients (91%) received adjuvant radiation therapy. With a median follow-up of 36 months (range, 0.6-141.4 months), 10 patients recurred. Of these, 2 (20%) were grade 1, 2 (20%) were grade 2, and 6 (60%) were grade 3. Nine (90%) of these recurrences had a distant component and 7 (70%) were fatal. Overall, the 3 year cumulative incidence failure rate for grade 1/2 tumors was 5.4%; for grade 3 tumors it was 28.9% (P<0.001). Age, BMI, and lymphovascular invasion were not associated with an increased risk of recurrence.
CONCLUSIONS: Patients with stage IC, grade 3 endometrial cancer had a significantly increased risk of recurrence (28.9%). All of these recurrences had a distant component and the majority were fatal. Further investigation into the addition of adjuvant systemic therapy in these high-risk patients is warranted. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22112609     DOI: 10.1016/j.ygyno.2011.11.020

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  4 in total

1.  Analysis of recurrence and survival rates in grade 3 endometrioid endometrial carcinoma.

Authors:  Jieyu Wang; Nan Jia; Qing Li; Chao Wang; Xiang Tao; Keqin Hua; Weiwei Feng
Journal:  Oncol Lett       Date:  2016-07-28       Impact factor: 2.967

2.  Adjuvant sequential chemo and radiotherapy improves the oncological outcome in high risk endometrial cancer.

Authors:  Mauro Signorelli; Andrea Alberto Lissoni; Elena De Ponti; Tommaso Grassi; Serena Ponti; Robert Fruscio
Journal:  J Gynecol Oncol       Date:  2015-07-14       Impact factor: 4.401

3.  Should the Optimal Adjuvant Treatment for Patients With Early-Stage Endometrial Cancer With High-Intermediate Risk Factors Depend on Tumor Grade?

Authors:  Chunyan Lan; Xin Huang; Qidan Huang; Yin Wang; Haifeng Gu; Yong Li; Jihong Liu
Journal:  Int J Gynecol Cancer       Date:  2015-10       Impact factor: 3.437

4.  Risk factors for recurrence amongst high intermediate risk patients with endometrioid adenocarcinoma.

Authors:  Agnes Y Bahng; Christina Chu; Paul Wileyto; Stephen Rubin; Lilie L Lin
Journal:  J Gynecol Oncol       Date:  2012-09-19       Impact factor: 4.401

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.